Patent Opportunities In FDA Bispecific Antibody Guidance

By Maria Doukas, Christopher Betti, Kathleen Sanzo and Richard Martin (August 13, 2019, 1:28 PM EDT) -- In April 2019, the U.S. Food and Drug Administration published draft guidance entitled "Bispecific Antibody Development Programs Guidance for Industry" that provides "recommendations to assist industry and other parties involved in the development of bispecific antibodies."[1] Based on three issues identified by the FDA as potentially important to regulatory approval of these products, companies may consider aligning their patent strategy with these regulatory requirements to acquire a competitive advantage. ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!